Menstrual history and quality-of-life outcomes in XXXX with @entity0 treated with adjuvant therapy on the NSABP B-30 trial.

@entity1 @entity632 @entity47404 @entity0 @entity440 @entity5 @entity786 @entity1205 @entity1866 @entity1129 @entity2588
PURPOSE: Premenopausal @entity1 with @entity0 receiving adjuvant chemotherapy are at risk for @entity2588 . The National Surgical Adjuvant Breast and Bowel Project B-30 trial included @entity1866 ( @entity1866 ) and quality-of-life (QOL) studies to compare treatments on these outcomes. @entity1 AND METHODS: @entity1 were randomly assigned to sequential @entity632 (A) and @entity786 (C) followed by @entity1205 (T; @entity47404 ), concurrent TAC, or @entity1129 , which varied in duration (24, 12, 12 weeks, respectively), and use of C. Endocrine therapy was prescribed for @entity1 with hormone receptor-positive @entity5 . @entity1866 and QOL were assessed with standardized questionnaires at baseline; cycle 4, day 1; and every 6 months through 24 months. Prespecified analyses examined rates of @entity2588 by treatment arm, the relationship between @entity2588 and QOL, and QOL by treatment arm. RESULTS: @entity2588 12 months after random assignment was significantly different between treatment groups: 69.8% for AC > T, 57.7% for TAC, and 37.9% for @entity1129 (P < .001). The @entity1129 group without @entity440 had the lowest rate of @entity2588 . QOL was poorer for @entity1 receiving AC > T at 6 months but similar to others by 12 months. Post-treatment symptoms were increased above baseline for all treatments. Multivariable repeated measures modeling demonstrated that treatment arm, time point, age, and @entity440 use were significantly associated with symptom severity (all P values < .002). CONCLUSION: @entity2588 rates differed significantly by treatment arm, with the @entity1129 arm having the lowest rate. @entity1 treated with longer duration therapy ( @entity47404 ) had greater symptom severity and poorer QOL at 6 months, but did not differ from shorter duration treatments at 12 months.
